THX Pharma
ALTHX.PA · PAR
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.04 | 0.04 | 0.06 | -0.07 |
| FCF Yield | -68.94% | -73.67% | -58.22% | -26.26% |
| EV / EBITDA | -2.80 | -1.51 | -2.04 | -2.79 |
| Quality | ||||
| ROIC | -516.23% | -116.64% | -53.86% | -46.89% |
| Gross Margin | -14.61% | -1,565.37% | 19.98% | -1,465,443.52% |
| Cash Conversion Ratio | 1.91 | 0.93 | 0.82 | 0.77 |
| Growth | ||||
| Revenue 3-Year CAGR | 76.55% | 689.58% | 12.09% | -89.78% |
| Free Cash Flow Growth | 46.87% | -18.23% | 15.40% | -6.68% |
| Safety | ||||
| Net Debt / EBITDA | -0.85 | -0.33 | -0.47 | 0.02 |
| Interest Coverage | -31.47 | -91.03 | -39.60 | -286.52 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -29.16 | -77.43 | -923.93 | 25,447.13 |